These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6515071)

  • 1. [Hypermineralocorticism secondary to the topical use of corticoids].
    Rama H; Carreras L; Martínez-Amenos A; Sarrias X
    Rev Clin Esp; 1984 Aug 15-31; 174(3-4):111-4. PubMed ID: 6515071
    [No Abstract]   [Full Text] [Related]  

  • 2. [Arterial hypertension secondary to the application of 9-alpha-fluoroprednisolone ointments].
    Arnal JM; Moneo MI; Loris C
    An Esp Pediatr; 1987 Jan; 26(1):65-6. PubMed ID: 3826948
    [No Abstract]   [Full Text] [Related]  

  • 3. [Exogenous hypermineralocorticism caused by a nasal spray containing 9-alpha fluoroprednisolone].
    Virgolini L; Geatti O; Giunta G
    Minerva Cardioangiol; 1984; 32(7-8):473-5. PubMed ID: 6208510
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hypertension and hypokalemia caused by a nasal spray containing fluorprednisolone acetate].
    Maiorano G; Loiacono N; Di Bello V; Contursi V; Castelnuovo F; Albano O
    Boll Soc Ital Cardiol; 1981; 26(5):465-71. PubMed ID: 7340877
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hypermineralcorticism syndrome secondary to topical application of 9-alpha-fluoroprednisolone (author's transl)].
    Vasconez F; Pérez-Garcia R; Olivas E; Bolívar JE; Valderrábano F
    Med Clin (Barc); 1980 Dec; 75(10):430-4. PubMed ID: 7464329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hypokalemic myopathy and metabolic alkalosis secondary to the topical application of 9-alpha-fluoroprednisolone].
    Pachón Diaz J; López Cortés L; Navarro Rodríguez A; García Criado F
    Rev Clin Esp; 1983 Sep; 170(5):221-2. PubMed ID: 6647945
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hypopotassemic myopathy caused by topical administration of 9 alpha fluoroprednisolone].
    Molins A; Alvarez-Sabín J; Montalbán J; Molero J; Alegre J; Codina A
    Neurologia; 1987; 2(5):244-6. PubMed ID: 3274232
    [No Abstract]   [Full Text] [Related]  

  • 8. Pseudoprimary aldosteronism from the topical application of 9-alpha-fluorprednisolone to the skin.
    Montoliu J; Botey A; Trilla A; Revert L
    Clin Nephrol; 1984 Nov; 22(5):262-6. PubMed ID: 6394185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhabdomyolysis, oedema and arterial hypertension: different syndromes related to topical use of 9-alpha-fluoroprednisolone.
    Lauzurica R; Bonal J; Bonet J; Romero R; Teixido J; Serra A; Caralps A
    J Hum Hypertens; 1988 Oct; 2(3):183-6. PubMed ID: 3236321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudohyperaldosteronism due to application of an antihemorrhoid cream.
    Marin F; González Quintela A; Moya M; Suárez E; de Zárraga M
    Nephron; 1989; 52(3):281-2. PubMed ID: 2739869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypokalemic alkalosis due to 9-alpha-fluoroprednisolone locally applied in pemphigus vulgaris].
    Scarpa C; Gentilli G
    G Ital Dermatol Venereol; 1983; 118(3):179-81. PubMed ID: 6546245
    [No Abstract]   [Full Text] [Related]  

  • 12. Factitious hypertension with mineralocorticoid excess in an infant.
    De Stefano P; Bongo IG; Borgna-Pignatti C; Severi F
    Helv Paediatr Acta; 1983 May; 38(2):185-9. PubMed ID: 6874387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypokalemic myopathy caused by fluoroprednisolone in a nasal spray. Observations 2 cases].
    Cantello R; Bergamini L; Delsedime M; Durelli L; Troni W; Gilli M; Cocito D
    Minerva Med; 1983 Jun; 74(25):1463-7. PubMed ID: 6856155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Again on the subject of arterial hypertension caused by the chronic cutaneous application of mineralocorticoids].
    Bisignani G; Boncompagni F; Plastina F
    Minerva Endocrinol; 1988; 13(1):16. PubMed ID: 3367885
    [No Abstract]   [Full Text] [Related]  

  • 15. [Excess mineralocorticoid syndrome secondary to nasal sprays containing 9 alpha-fluoroprednisolone].
    Foresti V; Parisio E; Ricci G
    Minerva Med; 1987 Sep; 78(17):1305-11. PubMed ID: 2444906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The etiology of a syndrome of factitious mineralocorticoid excess: a steroid-containing nasal spray.
    Funder JW; Adam WR; Mantero F; Kraft N; Ulick S
    J Clin Endocrinol Metab; 1979 Dec; 49(6):842-6. PubMed ID: 92477
    [No Abstract]   [Full Text] [Related]  

  • 17. Pseudoaldosteronism due to 9-alpha-fluoroprednisolone creams.
    Praga M; Maiz E; Mijares RP; Lopez de Novales E
    Clin Nephrol; 1983 Dec; 20(6):321. PubMed ID: 6641033
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hypokalemic myopathy, high levels of muscle enzymes and myocardial ischemia secondary to the topical administration of 9-alpha-fluoro-prednisolone].
    Cosentino F; Mantelli I; Cosentino F
    Clin Ter; 1986 Mar; 116(6):509-11. PubMed ID: 3720236
    [No Abstract]   [Full Text] [Related]  

  • 19. Mineralocorticoid hypertension due to a nasal spray containing 9 alpha-fluoroprednisolone.
    Mantero F; Armanini D; Opocher G; Fallo F; Sampieri L; Cuspidi B; Ambrosi C; Faglia G
    Am J Med; 1981 Sep; 71(3):352-7. PubMed ID: 6169277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis.
    Kurz PA; Chheda LV; Kurz DE
    Ocul Immunol Inflamm; 2011 Feb; 19(1):84-5. PubMed ID: 21034305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.